BDBM656475 US11919887, Compound 2::rel-(2S,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (1) and rel-(2R,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide

SMILES C[C@H]1[C@H]([C@@H](O[C@@]1(C)C(F)(F)F)C(=O)Nc1ccnc(c1)C(N)=O)c1ccc(F)cc1OC(F)F

InChI Key InChIKey=UZCWBEUZZFVIAI-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 656475   

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656475(US11919887, Compound 2 | rel-(2S,3R,4R,5S)-4-[[3-[...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent